The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN).
 
David Anthony Clump
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Heath Devin Skinner
No Relationships to Disclose
 
James Ohr
No Relationships to Disclose
 
Moon Jung Fenton
No Relationships to Disclose
 
Daniel Paul Normolle
No Relationships to Disclose
 
Jonathan Jay Beitler
No Relationships to Disclose
 
Julie E. Bauman
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CUE Biopharma (Inst); Lilly (Inst); Moderna Therapeutics (Inst); Novartis (Inst)
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Achilles Therapeutics; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; EMD Serono; Everest Clinical Research; F. Hoffmann LaRoche; F. Hoffmann LaRoche; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; Merck; Mirati Therapeutics; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Sanofi; Seagen; VIR Biotechnology; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro